UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

 

__________

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

 

October 21, 2016

 

__________

 

INTEGRATED BIOPHARMA, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

 

DELAWARE

(STATE OR OTHER JURISDICTION OF INCORPORATION)

 



		
			
			
001-31668
			
			
			
22-2407475
			
		





		
			
			
(COMMISSION FILE NUMBER)
			
			
			
(I.R.S. EMPLOYER IDENTIFICATION NO.)
			
		



 

225 Long Avenue

Hillside, New Jersey 07205

 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

 

(973) 926-0816

(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 



		
			
			
☐
			
			
			
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			
		



 



		
			
			
☐
			
			
			
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			
		



 



		
			
			
☐
			
			
			
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			
		



 



		
			
			
☐
			
			
			
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
			
		



 

 

HF 4478193v.4 #13332/0001

 


 

 


 


 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On October 21, 2016, Joseph LaPlaca notified the Board of Directors of Integrated Biopharma Inc. (the “Company”) that he does not wish to stand for re-election as a Director at the Company’s shareholders meeting to be held on November 28, 2016. His decision is not the result of any disagreement with the Company.

 

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

                       



		
			
			
Date: November 23, 2016
			
			
			
INTEGRATED BIOPHARMA, INC.
			
		
		
			 
			 
		
		
			 
			
			
By:     /s/ E. Gerald Kay           
			
		
		
			 
			
			
E. Gerald Kay
			
		
		
			 
			
			
President and Chief Executive Officer